DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Ombrabulin

Generic Name: Ombrabulin

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆N_₂O_₆

CAS Number: 181816-48-8

Unique Ingredient Identifier: 82JB1524Q6

Overview

Ombrabulin has been used in trials studying the treatment of Sarcoma, Neoplasms, Solid Tumor, Neoplasms, Malignant, and Advanced Solid Tumors, among others.

Background

Ombrabulin has been used in trials studying the treatment of Sarcoma, Neoplasms, Solid Tumor, Neoplasms, Malignant, and Advanced Solid Tumors, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors

Phase 1

Completed

Posted: 2013/07/25

Sponsor:Sanofi

Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel

Phase 2

Completed

Posted: 2011/04/11

Sponsor:Sanofi

A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors

Phase 1

Completed

Posted: 2011/02/10

Sponsor:Sanofi

Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer

Phase 2

Completed

Posted: 2010/12/21

Sponsor:Sanofi

Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

Phase 1

Completed

Posted: 2010/09/02

Sponsor:Sanofi

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy